Spectroscopy: UV-Vis spectra were recorded on a Perkin-Elmer Lambda 35 spectrophotometer or on a Varian Cary 50 spectrophotometer. CD spectra were recorded on an Applied Photophysics Chirascan spectropolarimeter. Luminescence spectra were recorded on a Cary Eclipse spectrometer. Phosphorescence lifetimes were measured in time-resolved mode on a Cary Eclipse spectrometer. UV-Vis, CD and Cary Eclipse luminescence spectrometers are equipped with a thermo-regulated cell holder and spectra were recorded at 298 K. Time-resolved emission studies were performed using degassed solutions at 20 °C using a frequency-tripled Nd:YAG amplified laser system (30 ps, 30 mJ @1064 nm, 20 Hz, Ekspla model PL 2143) whose output was used to pump an optical parametric generator (Ekspla model PG 401) producing tunable excitation pulses in the range 410-2300 nm. All light signals were analysed by a spectrograph (Princeton Instruments Acton model~SP2300) coupled with a high dynamic range streak camera (Hamamatsu Photonics C7700, 1 ns -1 ms). Data were analysed using an in-house written software developed in LabVIEW 2014 system-design platform and development environment. The trust-region dogleg algorithm [1] (supported by LabVIEW 2014) was applied to determine the set of parameters that best fit the set of input data. The trust-region dogleg algorithm was used instead of Levenberg-Marquardt algorithm, the latter being less stable in most cases during optimization process, because trust region methods are robust, and can be applied to ill-conditioned problems.
Peptide synthesis
Linear precursor: Peptide synthesis was performed by solid-phase peptide synthesis (SPPS) on NovaPEG HMPB resin (substitution 0.52 mmol/g, 250 mg, 0.13 mmol) using Fmoc chemistry. The coupling of the first amino acid (Gly) was performed manually as followed. Fmoc-Gly-OH (1.4 mmol, 416 mg) and DIPCDI (0.7 mmol, 0.1 mL) were dissolved in anhydrous DCM (8 mL) and DMF (4 mL) under argon. After stirring for 20 min, DCM was evaporated under reduced pressure. The solution was poured into the reactor containing the resin and DMAP (0.04 mmol, 5 mg) was added. After stirring for 30 min, the resin was washed with DMF and DCM.
Then, the linear precursor was assembled on a CEM Corporation Liberty1 peptide synthesizer. Fmoc removal was performed by two successive treatments with 20 % piperidine in DMF (10 and 5 min) at room temperature.
Coupling reactions were performed with N-α-Fmoc-protected amino acids (0.2 M in DMF, 5 eq.), PyBOP (0.5 M in DMF, 5 eq.) and DIEA (2 M in NMP, 10 eq.) for 30 min at room temperature, except for D Pro (double coupling, 1h each), Aib (activation with COMU instead of PyBOP, double coupling, 2h each) and the first Met (double coupling, 1h each). Each coupling was followed by a capping treatment performed with 2 % Ac2O in DMF and DIEA (2 M in NMP, 10 eq.) for 5 min at room temperature. Resin cleavage was performed using 1% TFA in DCM. The solution containing the protected peptide was evaporated under reduced pressure. The residue was dissolved in a minimum of DCM and Et2O was added to promote precipitation. The supernatant was removed and the solid was washed twice with Et2O and dried. It was used without further purification in the next step.
Cyclization:
The powder corresponding to the linear precursor was dissolved in degassed DMF (1 mg / 1 mL) and PyBOP (0.26 mmol, 2 eq., 137 mg) and DIEA (6.5 mmol, 60 eq., 1.1 mL) were added. The solution was stirred overnight at room temperature. The solvent was evaporated under reduced pressure and Et2O was added.
The supernatant was removed and the solid was washed twice with Et2O and dried. It was used without further purification in the next step.
Alloc removal:
The cyclic peptide was reacted with Pd(PPh3)4 (0.017 mmol, 0.1 eq., 20 mg) and phenylsilane (4.3 mmol, 25 eq., 0.5 mL) in degassed anhydrous DCM (20 mL) for 1h in the dark. The solution was evaporated under reduced pressure. The residue was dissolved in a minimum of DCM/MeOH (1:2) mixture before precipitation using Et2O. The supernatant was removed and the solid was washed twice with Et2O and dried. The product was used without further purification in the next step.
Coupling of DOTA-tris(tBu)ester:
The powder corresponding to the alloc-free cyclic peptide was dissolved in degassed DMF (8 mL). DOTA-tris(tBu)ester, (0.26 mmol, 0.15 mg), PyBOP (0.26 mmol, 135 mg) and DIEA (0.78 mmol, 0.5 mL) were added. The reaction mixture was stirred overnight at room temperature and the solvent was evaporated under reduced pressure. The residue was dissolved in a minimum of DCM/MeOH (1:2, v/v) mixture before precipitation using Et2O. The supernatant was removed and the solid was washed twice with Et2O and dried. It was used without further purification in the next step.
Removal of side-chain protecting groups:
The DOTA-substituted cyclic peptide was stirred for 4 h in a TFA/TIS/H2O/DTT/thioanisole/octylsulfide (18 mL / 0.6 mL / 0.6 mL / 650 mg / 300 mL / 300 mL) mixture. The solution was evaporated to yield a yellow oil, which was precipitated on adding cold Et2O. The crude peptide was purified by preparative RP-HPLC (gradient: 5 to 20% B in 3 min followed by 20 to 40% B in 15 min) to yield the free peptide as a white powder after freeze-drying. 4+ for M = C108H172N28O28S2). Tb by titration experiments using imidazole as a competitor. [2] Titrations were performed in HEPES buffer (10 mM, pH 7.5) containing the peptide (5-20 µM) and imidazole (1-10 mM). For , buffer contained NH2OH (2 mM) and Cu + was generated in situ by reduction of the added CuSO4 by NH2OH. Tb 3+ emission spectra (lex = 280 nm) were recorded after each addition of metal (equilibration is reached within a few seconds). The titrations ( Figure S9 ) were fitted using the program SPECFIT [3] [4, 5] which are reported in Table S1 . The competitive titration between LCC1(Aib) Tb (11.0 µM) and imidazole (1.0 mM) is shown in Figure S9 as an example. [LCC1(Aib) Tb ] = 11 µM, [imidazole] = 1 mM, [NH2OH] = 2 mM. The solid lines correspond to the fits obtained using SPECFIT [3] , which yielded log KCu = 10.3 (2).
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Determination of Cu
Circular dichroism
Preparation of samples for CD monitoring of Cu + and Ag + binding: Solutions were prepared as described above for luminescence monitoring but using a phosphate buffer (10 mM, pH 7.0) instead of HEPES. 
